Sanofi Gets EU Nod on Hemolytic Anemia Drug
18 November 2022 - 5:29AM
Dow Jones News
By Cecilia Butini
Sanofi SA said Thursday that the European Union gave marketing
authorization to a drug it developed to treat hemolytic anemia in
adult patients with cold agglutinin disease, an autommune disease
targeting red blood cells.
The French pharma company said that its drug, a monoclonal
antibody named Enjaymo, is currently the only approved treatment
for the disease.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
November 17, 2022 13:14 ET (18:14 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
